On Friday, Exact Sciences Corp (EXAS) stock saw a decline, ending the day at $51.48 which represents a decrease of $-1.75 or -3.29% from the prior close of $53.23. The stock opened at $53.14 and ...
Piper Sandler analyst David Westenberg lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $85 following quarterly ...
Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...
Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...
The lowered sales forecast, which analysts called a “shocking guidance update,” contributed to a 23% drop in the cancer ...
On Wednesday, Exact Sciences Corp (EXAS) stock saw a decline, ending the day at $54.72 which represents a decrease of $-16.79 or -23.48% from the prior close of $71.51. The stock opened at $55.7 and ...
Investor's Business Daily on MSN6d
Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken?Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year ...
Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...
Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tycho ...
Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.
Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback